Synergy Pharmaceuticals Inc (SGYP) 8.14 $SGYP
3 Great Values to Buy on the Nasdaq - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 9:42AM CDT
Since the long term holds good for stocks listed on the Nasdaq, it will be a prudent idea to invest in value stocks despite short-term volatility.
SGYP: 8.14 (-0.05), AMZN: 527.31 (-4.10), BIIB: 319.06 (+9.63), TTMI: 9.20 (+0.06), FB: 95.31 (+1.14), NFLX: 107.40 (+0.97), YHOO: 37.77 (-0.06), QCOM: 63.29 (+1.31), GOOGL: 659.13 (+0.86), ANAC: 151.91 (+7.61), MSFT: 45.46 (+0.11), TECD: 56.52 (+1.00), AAPL: 123.90 (+1.13)
Technical Report on Drug Manufacturers - Other Stocks -- Synergy Pharma, Teva Pharma, Orexigen Therapeutics, Prana Biotechnology, and Sucampo Pharma
PR Newswire - Fri Jul 24, 8:00AM CDT
Equity Research Institute has initiated coverage on the following equities: Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Orexigen Therapeutics Inc. (NASDAQ: OREX), Prana Biotechnology Ltd (NASDAQ: PRAN), and Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP). Free research report on Synergy Pharma can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=SYGP On Thursday, July 23, 2015, the NASDAQ Composite ended at 5,146.41, down 0.49%, the Dow Jones Industrial Average declined 0.67%, to finish the day at 17,731.92, and the S&P 500 closed at 2,102.15, down 0.57%. The losses were broad based as eight out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
SGYP: 8.14 (-0.05), OREX: 4.36 (+0.15), SCMP: 23.19 (+1.55), TEVA: 70.94 (-1.06), PRAN: 1.16 (+0.01)
Market Losing Some Good Hiding Places
at The Street - Thu Jul 23, 3:27PM CDT
'Good' action gets narrower as breadth worsens.
CI: 145.95 (+0.05), SGYP: 8.14 (-0.05), NFLX: 107.40 (+0.97), TSLA: 264.35 (+11.34), AMZN: 527.31 (-4.10), IBM: 160.07 (+1.00), FB: 95.31 (+1.14), CRUS: 34.25 (+1.35), GOOGL: 659.13 (+0.86), FTNT: 47.04 (-0.06), AAPL: 123.90 (+1.13), ADPT: 106.10 (-0.55)
Don't Let the Indices Fool You
at The Street - Thu Jul 23, 12:24PM CDT
The market action is not as good as it seems.
CI: 145.95 (+0.05), SGYP: 8.14 (-0.05), NFLX: 107.40 (+0.97), TSLA: 264.35 (+11.34), AMZN: 527.31 (-4.10), IBM: 160.07 (+1.00), FB: 95.31 (+1.14), CRUS: 34.25 (+1.35), GOOGL: 659.13 (+0.86), FTNT: 47.04 (-0.06), AAPL: 123.90 (+1.13), ADPT: 106.10 (-0.55)
Led by Laggards
at The Street - Thu Jul 23, 9:37AM CDT
Oil, semiconductors, gold and cybersecurity names are now leading.
CI: 145.95 (+0.05), SGYP: 8.14 (-0.05), NFLX: 107.40 (+0.97), AMZN: 527.31 (-4.10), IBM: 160.07 (+1.00), FB: 95.31 (+1.14), CRUS: 34.25 (+1.35), GOOGL: 659.13 (+0.86), FTNT: 47.04 (-0.06), AAPL: 123.90 (+1.13), ADPT: 106.10 (-0.55)
The Zacks Analyst Blog Highlights: Google, Netflix, Anacor Pharmaceuticals, Synergy Pharmaceuticals, Advanced Energy Industries, TTM Technologies and TransAct Technologies - Press Releases
Zacks Equity Research - Zacks Investment Research - Wed Jul 22, 8:30AM CDT
The Zacks Analyst Blog Highlights: Google, Netflix, Anacor Pharmaceuticals, Synergy Pharmaceuticals, Advanced Energy Industries, TTM Technologies and TransAct Technologies
SGYP: 8.14 (-0.05), NFLX: 107.40 (+0.97), TACT: 7.20 (-0.01), TTMI: 9.20 (+0.06), ANAC: 151.91 (+7.61), GOOGL: 659.13 (+0.86), AEIS: 25.94 (-0.10)
3 Nasdaq Stocks to Buy for Growth - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 21, 9:34AM CDT
The tech-laden Nasdaq ekes out another closing high amid earnings.
SGYP: 8.14 (-0.05), NFLX: 107.40 (+0.97), HAS: 79.60 (+0.09), TACT: 7.20 (-0.01), TTMI: 9.20 (+0.06), EBAY: 28.23 (+0.23), GOOGL: 659.13 (+0.86), ANAC: 151.91 (+7.61), MSFT: 45.46 (+0.11), INTC: 29.04 (+0.69), AAPL: 123.90 (+1.13), AEIS: 25.94 (-0.10)
An Odd Mix of Action
at The Street - Mon Jul 20, 3:13PM CDT
A few big-cap names drove minor gains in the indices.
AMBA: 121.53 (+2.08), SGYP: 8.14 (-0.05), SEDG: 30.25 (+2.26), NFLX: 107.40 (+0.97), GPRO: 62.95 (+1.68), TSLA: 264.35 (+11.34), AMZN: 527.31 (-4.10), ANTH: 11.01 (-0.14), FB: 95.31 (+1.14), GOOGL: 659.13 (+0.86), AAPL: 123.90 (+1.13)
This Action Is Deceptive
at The Street - Mon Jul 20, 12:18PM CDT
Facebook, Tesla create illusion that the action is better than it really is.
SGYP: 8.14 (-0.05), SEDG: 30.25 (+2.26), NFLX: 107.40 (+0.97), TSLA: 264.35 (+11.34), AMZN: 527.31 (-4.10), ANTH: 11.01 (-0.14), FB: 95.31 (+1.14), GOOGL: 659.13 (+0.86)
Don't Overreact if Charts Start Basing
at The Street - Mon Jul 20, 9:33AM CDT
Current weakness is not necessarily a negative sign.
SGYP: 8.14 (-0.05), SEDG: 30.25 (+2.26), NFLX: 107.40 (+0.97), AMZN: 527.31 (-4.10), ANTH: 11.01 (-0.14), FB: 95.31 (+1.14), GOOGL: 659.13 (+0.86)
Global Opioid-Induced Constipation Market Report 2015-2019 - Availability of OTC and Off-label Drugs a Major Challenge
M2 - Fri Jul 17, 4:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fbgbsl/global) has announced the addition of the "Global Opioid-Induced Constipation Market 2015-2019" report to their offering. The global opioid-induced constipation market to grow at a CAGR of 30.18% over the period 2014-2019. This report covers the present scenario and the growth prospects of the global opioid-induced constipation market for 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of opioid-induced constipation, which includes branded drugs, off-label products, and OTC drugs. Some of the common symptoms of opioid-induced constipation are hard and dry stools, painful defecation, bloating, distention and bulged abdomen, feeling lethargic, and loss of appetite. Opioid-induced constipation can be managed by changing lifestyle along with the use of targeted therapies and other OTC and off-label drugs. The market was served by various off-label and OTC therapies to treat the condition. However, in 2008, Relistor, a targeted therapy for treating opioid-induced constipation, was approved by the US FDA and the EMA. This drug is a peripherally acting mu-opioid receptor antagonist and was the first targeted therapy to obtain approval for this indication. Movantik/Moventig, also a peripherally acting mu-opioid receptor antagonist, was approved by the US FDA and the EMA in 2014 and is a targeted therapy for this indication. These drugs reduce the undesirable effects of the opioid analgesics without affecting its analgesic effects. Therefore, these drugs are increasingly becoming the preferred medication to treat opioid-induced constipation. According to the report, the low levels of awareness about opioid-induced constipation among patients and the medical fraternity have resulted in the usage of off-label and OTC medications as the treatment options. However, these drugs are only partially successful in treating this condition. The entry of peripherally acting mu-opioid receptor antagonists such as Movantik/Moventig has driven the market significantly. The drug targets the underlying cause of opioid-induced constipation without affecting the analgesic action of the opioid drugs. Therefore, this is increasingly becoming the preferred treatment option for opioid-induced constipation. Further, the report states that the availability of OTC and off-label drugs restricts the market growth. On the basis of the mechanism of action of drugs, the market is grouped into the following categories: - Peripherally Acting Mu-opioid Receptor Antagonist - Locally Acting Chloride Channel Activator - Others On the basis of the route of administration of drugs, the market is grouped into the following categories: - Oral - Parenteral On the basis of the dosage form of drugs, the market is grouped into the following categories: - Solid - Liquid Key Vendors - AstraZeneca - Takeda Pharmaceutical - Valeant Pharmaceuticals International Other Prominent Vendors - Abbott - Bayer - Boehringer Ingelheim - C.B. Fleet - Cosmo Pharmaceuticals - Daewoong - Daiichi Sankyo - GlaxoSmithKline - Ironwood Pharmaceuticals - Johnson & Johnson - Merck - Mundipharma - Nektar Therapeutics - Pfizer - Progenics Pharmaceuticals - Shionogi - SLA Pharma - Sucampo - Synergy Pharmaceuticals - Theravance For more information visit http://www.researchandmarkets.com/research/fbgbsl/global
SGYP: 8.14 (-0.05), PGNX: 9.36 (+0.23), JNJ: 99.22 (+0.94), IRWD: 10.52 (+0.07), MRK: 57.28 (+0.29), GSK: 41.72 (+0.12), NKTR: 12.89 (+0.47), VRX.TO: 333.03 (-4.46)
Market's Not in the Mood to Move
at The Street - Wed Jul 15, 3:24PM CDT
Attention turns to earnings and away from Greece, Fed.
SGYP: 8.14 (-0.05), BLUE: 159.15 (-0.34), AMBA: 121.53 (+2.08), NFLX: 107.40 (+0.97), EYES: 14.05 (-0.31), AMZN: 527.31 (-4.10), ZIOP: 12.53 (+0.50), LNKD: 228.00 (+7.34), FB: 95.31 (+1.14), RCPT: 227.90 (+0.81), LBIO: 8.87 (+0.08), INTC: 29.04 (+0.69), ONTY: 3.50 (+0.15), CELG: 135.70 (+3.14)
Market Shrugs Off Yellen
at The Street - Wed Jul 15, 12:25PM CDT
She didn't say anything to spook the market, but didn't say anything bullish either.
SGYP: 8.14 (-0.05), BLUE: 159.15 (-0.34), AMBA: 121.53 (+2.08), NFLX: 107.40 (+0.97), EYES: 14.05 (-0.31), AMZN: 527.31 (-4.10), ZIOP: 12.53 (+0.50), LNKD: 228.00 (+7.34), FB: 95.31 (+1.14), RCPT: 227.90 (+0.81), LBIO: 8.87 (+0.08), INTC: 29.04 (+0.69), ONTY: 3.50 (+0.15), CELG: 135.70 (+3.14)
An Excuse for a Little Profit-Taking
at The Street - Wed Jul 15, 9:25AM CDT
The market needs some consolidation after a four-day run.
SGYP: 8.14 (-0.05), BLUE: 159.15 (-0.34), AMBA: 121.53 (+2.08), NFLX: 107.40 (+0.97), EYES: 14.05 (-0.31), AMZN: 527.31 (-4.10), ZIOP: 12.53 (+0.50), LNKD: 228.00 (+7.34), FB: 95.31 (+1.14), RCPT: 227.90 (+0.81), LBIO: 8.87 (+0.08), INTC: 29.04 (+0.69), ONTY: 3.50 (+0.15), CELG: 135.70 (+3.14)
V-Shaped Move Makes a Comeback
at The Street - Tue Jul 14, 3:15PM CDT
Market grinds higher as bulls have the ball.
AMBA: 121.53 (+2.08), SGYP: 8.14 (-0.05), NFLX: 107.40 (+0.97), GPRO: 62.95 (+1.68), AMZN: 527.31 (-4.10), MU: 19.98 (+1.86), GUID: 9.35 (unch), FB: 95.31 (+1.14), GOOGL: 659.13 (+0.86), INTC: 29.04 (+0.69), MBLY: 59.08 (+0.29)
Looking for New Buys
at The Street - Tue Jul 14, 12:46PM CDT
Still a challenge to put money to work, but big-picture worries are now reduced.
AMBA: 121.53 (+2.08), SGYP: 8.14 (-0.05), NFLX: 107.40 (+0.97), GPRO: 62.95 (+1.68), AMZN: 527.31 (-4.10), MU: 19.98 (+1.86), GUID: 9.35 (unch), FB: 95.31 (+1.14), GOOGL: 659.13 (+0.86), INTC: 29.04 (+0.69), MBLY: 59.08 (+0.29)
A Good-Looking Market to Trade
at The Street - Tue Jul 14, 9:24AM CDT
The focus has shifted away from the macro and back to stock picking.
AMBA: 121.53 (+2.08), SGYP: 8.14 (-0.05), NFLX: 107.40 (+0.97), GPRO: 62.95 (+1.68), AMZN: 527.31 (-4.10), MU: 19.98 (+1.86), GUID: 9.35 (unch), FB: 95.31 (+1.14), GOOGL: 659.13 (+0.86), INTC: 29.04 (+0.69), MBLY: 59.08 (+0.29)
3 Biotech Stocks That Could Soon Rocket Higher
Todd Campbell, The Motley Fool - Motley Fool - Tue Jul 14, 6:55AM CDT
Source: Flickr user Steve Jurvetson Biotech stocks can pop or drop on the faintest of whims and whispers, so I don't think it's a stretch to think that upcoming trial results from three companies could result in a significant move higher or lower...
SGYP: 8.14 (-0.05), GILD: 112.50 (+1.96), ONCE: 61.44 (-0.52)
Ironwood/AstraZeneca to File for Linzess in China in 2016 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 09, 2:45PM CDT
Ironwood Pharmaceuticals (IRWD) and AstraZeneca report positive top-line phase III data on Linzess; the companies will file for its approval in China in early 2016.
SGYP: 8.14 (-0.05), AGN: 337.53 (+10.55), IRWD: 10.52 (+0.07), AZN: 32.85 (+0.14)
Galmed Inks Deal to Develop Non-Invasive Diagnostic Tool - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 09, 11:40AM CDT
Galmed Pharmaceuticals (GLMD) inked a deal with One Way Liver Genomics for developing a non-invasive, companion diagnostic tool for aramchol.
SGYP: 8.14 (-0.05), GLMD: 10.10 (+0.03), ADHD: 7.47 (-0.24), BIOD: 1.03 (unch)
3 Great Values to Buy on the Nasdaq - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 9:42AM CDT
Since the long term holds good for stocks listed on the Nasdaq, it will be a prudent idea to invest in value stocks despite short-term volatility.
SGYP: 8.14 (-0.05), AMZN: 527.31 (-4.10), BIIB: 319.06 (+9.63), TTMI: 9.20 (+0.06), FB: 95.31 (+1.14), NFLX: 107.40 (+0.97), YHOO: 37.77 (-0.06), QCOM: 63.29 (+1.31), GOOGL: 659.13 (+0.86), ANAC: 151.91 (+7.61), MSFT: 45.46 (+0.11), TECD: 56.52 (+1.00), AAPL: 123.90 (+1.13)
Technical Report on Drug Manufacturers - Other Stocks -- Synergy Pharma, Teva Pharma, Orexigen Therapeutics, Prana Biotechnology, and Sucampo Pharma
PR Newswire - Fri Jul 24, 8:00AM CDT
Equity Research Institute has initiated coverage on the following equities: Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Orexigen Therapeutics Inc. (NASDAQ: OREX), Prana Biotechnology Ltd (NASDAQ: PRAN), and Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP). Free research report on Synergy Pharma can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=SYGP On Thursday, July 23, 2015, the NASDAQ Composite ended at 5,146.41, down 0.49%, the Dow Jones Industrial Average declined 0.67%, to finish the day at 17,731.92, and the S&P 500 closed at 2,102.15, down 0.57%. The losses were broad based as eight out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
SGYP: 8.14 (-0.05), OREX: 4.36 (+0.15), SCMP: 23.19 (+1.55), TEVA: 70.94 (-1.06), PRAN: 1.16 (+0.01)
Market Losing Some Good Hiding Places
at The Street - Thu Jul 23, 3:27PM CDT
'Good' action gets narrower as breadth worsens.
CI: 145.95 (+0.05), SGYP: 8.14 (-0.05), NFLX: 107.40 (+0.97), TSLA: 264.35 (+11.34), AMZN: 527.31 (-4.10), IBM: 160.07 (+1.00), FB: 95.31 (+1.14), CRUS: 34.25 (+1.35), GOOGL: 659.13 (+0.86), FTNT: 47.04 (-0.06), AAPL: 123.90 (+1.13), ADPT: 106.10 (-0.55)
Don't Let the Indices Fool You
at The Street - Thu Jul 23, 12:24PM CDT
The market action is not as good as it seems.
CI: 145.95 (+0.05), SGYP: 8.14 (-0.05), NFLX: 107.40 (+0.97), TSLA: 264.35 (+11.34), AMZN: 527.31 (-4.10), IBM: 160.07 (+1.00), FB: 95.31 (+1.14), CRUS: 34.25 (+1.35), GOOGL: 659.13 (+0.86), FTNT: 47.04 (-0.06), AAPL: 123.90 (+1.13), ADPT: 106.10 (-0.55)
Led by Laggards
at The Street - Thu Jul 23, 9:37AM CDT
Oil, semiconductors, gold and cybersecurity names are now leading.
CI: 145.95 (+0.05), SGYP: 8.14 (-0.05), NFLX: 107.40 (+0.97), AMZN: 527.31 (-4.10), IBM: 160.07 (+1.00), FB: 95.31 (+1.14), CRUS: 34.25 (+1.35), GOOGL: 659.13 (+0.86), FTNT: 47.04 (-0.06), AAPL: 123.90 (+1.13), ADPT: 106.10 (-0.55)
The Zacks Analyst Blog Highlights: Google, Netflix, Anacor Pharmaceuticals, Synergy Pharmaceuticals, Advanced Energy Industries, TTM Technologies and TransAct Technologies - Press Releases
Zacks Equity Research - Zacks Investment Research - Wed Jul 22, 8:30AM CDT
The Zacks Analyst Blog Highlights: Google, Netflix, Anacor Pharmaceuticals, Synergy Pharmaceuticals, Advanced Energy Industries, TTM Technologies and TransAct Technologies
SGYP: 8.14 (-0.05), NFLX: 107.40 (+0.97), TACT: 7.20 (-0.01), TTMI: 9.20 (+0.06), ANAC: 151.91 (+7.61), GOOGL: 659.13 (+0.86), AEIS: 25.94 (-0.10)
3 Nasdaq Stocks to Buy for Growth - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 21, 9:34AM CDT
The tech-laden Nasdaq ekes out another closing high amid earnings.
SGYP: 8.14 (-0.05), NFLX: 107.40 (+0.97), HAS: 79.60 (+0.09), TACT: 7.20 (-0.01), TTMI: 9.20 (+0.06), EBAY: 28.23 (+0.23), GOOGL: 659.13 (+0.86), ANAC: 151.91 (+7.61), MSFT: 45.46 (+0.11), INTC: 29.04 (+0.69), AAPL: 123.90 (+1.13), AEIS: 25.94 (-0.10)
An Odd Mix of Action
at The Street - Mon Jul 20, 3:13PM CDT
A few big-cap names drove minor gains in the indices.
AMBA: 121.53 (+2.08), SGYP: 8.14 (-0.05), SEDG: 30.25 (+2.26), NFLX: 107.40 (+0.97), GPRO: 62.95 (+1.68), TSLA: 264.35 (+11.34), AMZN: 527.31 (-4.10), ANTH: 11.01 (-0.14), FB: 95.31 (+1.14), GOOGL: 659.13 (+0.86), AAPL: 123.90 (+1.13)
This Action Is Deceptive
at The Street - Mon Jul 20, 12:18PM CDT
Facebook, Tesla create illusion that the action is better than it really is.
SGYP: 8.14 (-0.05), SEDG: 30.25 (+2.26), NFLX: 107.40 (+0.97), TSLA: 264.35 (+11.34), AMZN: 527.31 (-4.10), ANTH: 11.01 (-0.14), FB: 95.31 (+1.14), GOOGL: 659.13 (+0.86)
Don't Overreact if Charts Start Basing
at The Street - Mon Jul 20, 9:33AM CDT
Current weakness is not necessarily a negative sign.
SGYP: 8.14 (-0.05), SEDG: 30.25 (+2.26), NFLX: 107.40 (+0.97), AMZN: 527.31 (-4.10), ANTH: 11.01 (-0.14), FB: 95.31 (+1.14), GOOGL: 659.13 (+0.86)
Global Opioid-Induced Constipation Market Report 2015-2019 - Availability of OTC and Off-label Drugs a Major Challenge
M2 - Fri Jul 17, 4:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fbgbsl/global) has announced the addition of the "Global Opioid-Induced Constipation Market 2015-2019" report to their offering. The global opioid-induced constipation market to grow at a CAGR of 30.18% over the period 2014-2019. This report covers the present scenario and the growth prospects of the global opioid-induced constipation market for 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of opioid-induced constipation, which includes branded drugs, off-label products, and OTC drugs. Some of the common symptoms of opioid-induced constipation are hard and dry stools, painful defecation, bloating, distention and bulged abdomen, feeling lethargic, and loss of appetite. Opioid-induced constipation can be managed by changing lifestyle along with the use of targeted therapies and other OTC and off-label drugs. The market was served by various off-label and OTC therapies to treat the condition. However, in 2008, Relistor, a targeted therapy for treating opioid-induced constipation, was approved by the US FDA and the EMA. This drug is a peripherally acting mu-opioid receptor antagonist and was the first targeted therapy to obtain approval for this indication. Movantik/Moventig, also a peripherally acting mu-opioid receptor antagonist, was approved by the US FDA and the EMA in 2014 and is a targeted therapy for this indication. These drugs reduce the undesirable effects of the opioid analgesics without affecting its analgesic effects. Therefore, these drugs are increasingly becoming the preferred medication to treat opioid-induced constipation. According to the report, the low levels of awareness about opioid-induced constipation among patients and the medical fraternity have resulted in the usage of off-label and OTC medications as the treatment options. However, these drugs are only partially successful in treating this condition. The entry of peripherally acting mu-opioid receptor antagonists such as Movantik/Moventig has driven the market significantly. The drug targets the underlying cause of opioid-induced constipation without affecting the analgesic action of the opioid drugs. Therefore, this is increasingly becoming the preferred treatment option for opioid-induced constipation. Further, the report states that the availability of OTC and off-label drugs restricts the market growth. On the basis of the mechanism of action of drugs, the market is grouped into the following categories: - Peripherally Acting Mu-opioid Receptor Antagonist - Locally Acting Chloride Channel Activator - Others On the basis of the route of administration of drugs, the market is grouped into the following categories: - Oral - Parenteral On the basis of the dosage form of drugs, the market is grouped into the following categories: - Solid - Liquid Key Vendors - AstraZeneca - Takeda Pharmaceutical - Valeant Pharmaceuticals International Other Prominent Vendors - Abbott - Bayer - Boehringer Ingelheim - C.B. Fleet - Cosmo Pharmaceuticals - Daewoong - Daiichi Sankyo - GlaxoSmithKline - Ironwood Pharmaceuticals - Johnson & Johnson - Merck - Mundipharma - Nektar Therapeutics - Pfizer - Progenics Pharmaceuticals - Shionogi - SLA Pharma - Sucampo - Synergy Pharmaceuticals - Theravance For more information visit http://www.researchandmarkets.com/research/fbgbsl/global
SGYP: 8.14 (-0.05), PGNX: 9.36 (+0.23), JNJ: 99.22 (+0.94), IRWD: 10.52 (+0.07), MRK: 57.28 (+0.29), GSK: 41.72 (+0.12), NKTR: 12.89 (+0.47), VRX.TO: 333.03 (-4.46)
Market's Not in the Mood to Move
at The Street - Wed Jul 15, 3:24PM CDT
Attention turns to earnings and away from Greece, Fed.
SGYP: 8.14 (-0.05), BLUE: 159.15 (-0.34), AMBA: 121.53 (+2.08), NFLX: 107.40 (+0.97), EYES: 14.05 (-0.31), AMZN: 527.31 (-4.10), ZIOP: 12.53 (+0.50), LNKD: 228.00 (+7.34), FB: 95.31 (+1.14), RCPT: 227.90 (+0.81), LBIO: 8.87 (+0.08), INTC: 29.04 (+0.69), ONTY: 3.50 (+0.15), CELG: 135.70 (+3.14)
Market Shrugs Off Yellen
at The Street - Wed Jul 15, 12:25PM CDT
She didn't say anything to spook the market, but didn't say anything bullish either.
SGYP: 8.14 (-0.05), BLUE: 159.15 (-0.34), AMBA: 121.53 (+2.08), NFLX: 107.40 (+0.97), EYES: 14.05 (-0.31), AMZN: 527.31 (-4.10), ZIOP: 12.53 (+0.50), LNKD: 228.00 (+7.34), FB: 95.31 (+1.14), RCPT: 227.90 (+0.81), LBIO: 8.87 (+0.08), INTC: 29.04 (+0.69), ONTY: 3.50 (+0.15), CELG: 135.70 (+3.14)
An Excuse for a Little Profit-Taking
at The Street - Wed Jul 15, 9:25AM CDT
The market needs some consolidation after a four-day run.
SGYP: 8.14 (-0.05), BLUE: 159.15 (-0.34), AMBA: 121.53 (+2.08), NFLX: 107.40 (+0.97), EYES: 14.05 (-0.31), AMZN: 527.31 (-4.10), ZIOP: 12.53 (+0.50), LNKD: 228.00 (+7.34), FB: 95.31 (+1.14), RCPT: 227.90 (+0.81), LBIO: 8.87 (+0.08), INTC: 29.04 (+0.69), ONTY: 3.50 (+0.15), CELG: 135.70 (+3.14)
V-Shaped Move Makes a Comeback
at The Street - Tue Jul 14, 3:15PM CDT
Market grinds higher as bulls have the ball.
AMBA: 121.53 (+2.08), SGYP: 8.14 (-0.05), NFLX: 107.40 (+0.97), GPRO: 62.95 (+1.68), AMZN: 527.31 (-4.10), MU: 19.98 (+1.86), GUID: 9.35 (unch), FB: 95.31 (+1.14), GOOGL: 659.13 (+0.86), INTC: 29.04 (+0.69), MBLY: 59.08 (+0.29)
Looking for New Buys
at The Street - Tue Jul 14, 12:46PM CDT
Still a challenge to put money to work, but big-picture worries are now reduced.
AMBA: 121.53 (+2.08), SGYP: 8.14 (-0.05), NFLX: 107.40 (+0.97), GPRO: 62.95 (+1.68), AMZN: 527.31 (-4.10), MU: 19.98 (+1.86), GUID: 9.35 (unch), FB: 95.31 (+1.14), GOOGL: 659.13 (+0.86), INTC: 29.04 (+0.69), MBLY: 59.08 (+0.29)
A Good-Looking Market to Trade
at The Street - Tue Jul 14, 9:24AM CDT
The focus has shifted away from the macro and back to stock picking.
AMBA: 121.53 (+2.08), SGYP: 8.14 (-0.05), NFLX: 107.40 (+0.97), GPRO: 62.95 (+1.68), AMZN: 527.31 (-4.10), MU: 19.98 (+1.86), GUID: 9.35 (unch), FB: 95.31 (+1.14), GOOGL: 659.13 (+0.86), INTC: 29.04 (+0.69), MBLY: 59.08 (+0.29)
3 Biotech Stocks That Could Soon Rocket Higher
Todd Campbell, The Motley Fool - Motley Fool - Tue Jul 14, 6:55AM CDT
Source: Flickr user Steve Jurvetson Biotech stocks can pop or drop on the faintest of whims and whispers, so I don't think it's a stretch to think that upcoming trial results from three companies could result in a significant move higher or lower...
SGYP: 8.14 (-0.05), GILD: 112.50 (+1.96), ONCE: 61.44 (-0.52)
Ironwood/AstraZeneca to File for Linzess in China in 2016 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 09, 2:45PM CDT
Ironwood Pharmaceuticals (IRWD) and AstraZeneca report positive top-line phase III data on Linzess; the companies will file for its approval in China in early 2016.
SGYP: 8.14 (-0.05), AGN: 337.53 (+10.55), IRWD: 10.52 (+0.07), AZN: 32.85 (+0.14)
Galmed Inks Deal to Develop Non-Invasive Diagnostic Tool - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 09, 11:40AM CDT
Galmed Pharmaceuticals (GLMD) inked a deal with One Way Liver Genomics for developing a non-invasive, companion diagnostic tool for aramchol.
SGYP: 8.14 (-0.05), GLMD: 10.10 (+0.03), ADHD: 7.47 (-0.24), BIOD: 1.03 (unch)
